Heliogenomics collaboration weighs on Quest Diagnostics stock amid heavy selling pressure and range-bound trade

Heliogenomics collaboration weighs on Quest Diagnostics stock amid heavy selling pressure and range-bound trade
Quest Diagnostics slides 1.33% today

Quest Diagnostics announced an arrangement that enables Heliogenomics to use its scale to reach more patients and their care teams.

Asia Chang, vice president and general manager of Oncology at Quest Diagnostics, described the expanded reach achievable through this arrangement. Details are based on a recent tweet.

Highlights

  • DGX trades below short- and medium-term moving averages, indicating continued bearish momentum despite holding above long-term support.
  • Momentum and oscillator indicators confirm selling pressure, with weak trend strength and intraday action dominated by sellers.
  • Near-term price likely consolidates between $194 and $200, with a high probability of range-bound trade barring a break below $193.80 or above $200.10.

DGX ($195.51) is currently trading below its MA-20 ($199.89) and MA-50 ($197.16), indicating ongoing short- and medium-term bearish pressure, while remaining above the long-term MA-200 ($184.00), which signals underlying support over the longer horizon. The Ichimoku Kijun at $203.48 stands as immediate resistance, with near-term support seen at MA-50 ($197.16) and key support at MA-200 ($184.00); immediate resistance is set by the Kijun ($203.48), and a secondary resistance at MA-20 ($199.89).

Momentum indicators on D1 show a bearish bias, with MACD signaling sell and weak trend confirmation from ADX (13.99, neutral). Oscillators point toward selling pressure: RSI sits at 42.93 (sell), Stoch RSI gives a strong sell (38.96), and CCI is negative at –80.00 (sell), with BBP indicating buyers are currently overbought but sellers dominate intraday action. In today’s session, DGX has declined 1.33%, reflecting notable downward pressure toward the bottom of the weekly range. DGX is trading at $195.51, up slightly from last week’s close of $195.26, marking a modest 0.13% gain, but with price sitting at the very bottom of the weekly range and weekly volatility at 4.70%. The weekly move suggests consolidation after a steady pullback from the high.

For the coming week, the expected trading band is $193.80 to $200.10, framing the price just above the 52-week low ($157.20) and about 8% below the 52-week high ($213.50). Based on W1 trend indicators (RSI, ADX, MACD, and MA-50), the probability of an upward move is very high (more than 80%), making a downward breakout less likely. The baseline scenario is range-bound trade between $194 and $200 as price consolidates near support. In the bullish case, if resistance at $200.10 is breached, a push toward the Kijun at $203.48 is possible. On the bearish side, a drop below near-term support at $193.80 would expose key long-term support at $184.00.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.